Adding Lynparza to Presurgical Chemo May Not Boost TNBC Outcomes

The addition of Lynparza to presurgical chemotherapy did not improve outcomes for patients with basal-like BRCA wild-type triple-negative breast cancer.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,San Francisco ,California ,United States ,Karen Pinilla Alba ,Department Of Oncology ,Trial Consortium ,University Of Cambridge Cancer Research ,United Kingdom Cancer Centre ,University Of California ,Helen Diller Family Comprehensive Cancer Center ,Adding Lynparza ,Cambridge Cancer Research ,Triple Negative Breast Cancer ,Ntnbc ,